IMS 2025 | Risk stratification in smoldering myeloma: current standards and emerging advances
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current standard and future of risk stratification in smoldering myeloma. She highlights that the incorporation of genomic, circulating tumor cell, immune, and other markers, will provide a more precise way to identify high-risk patients and tailor treatment decisions. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So there are so many different ways we can risk stratify our patients. Currently the standard of care is the 2/20/20 model or the IMWG model, but we know that that does not give us the dynamic changes and we’re hoping that the Pangea model, which is a publication from really everyone around the world, trying to say can we add to 2/20/20 by using dynamic or trajectory models to really understand how the different values change over time...
So there are so many different ways we can risk stratify our patients. Currently the standard of care is the 2/20/20 model or the IMWG model, but we know that that does not give us the dynamic changes and we’re hoping that the Pangea model, which is a publication from really everyone around the world, trying to say can we add to 2/20/20 by using dynamic or trajectory models to really understand how the different values change over time. And we’re hoping that that new model would be available for everyone as a patient, but also for physicians to really stratify patients better. We hope genomics, circulating tumor cells, immune, and other markers can help us truly identify who is that patient who is at risk of developing myeloma in the next two years. And then we can be more precise in our decision to treat them. And then the choice of therapy should be available for them. And the ones who are very high risk, maybe you will be treated in a different way than those who are less high risk.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen: Consultancy, Other: Speaker fees; GlaxoSmithKline: Consultancy; Standard Biotools: Other: Speaker fees; Aptitude Health: Consultancy; Pfizer: Consultancy, Other: Speaker fees; Takeda: Consultancy, Other: Speaker fees; Binding Site, part of Thermo Fisher Scientific: Consultancy; CurioScience: Consultancy, Other: Speaker fees; Huron Consulting: Consultancy; Janssen: Consultancy, Other: Speaker fees; Window Therapeutics: Consultancy; Menarini Silicon Biosystems: Consultancy, Other: Speaker fees; Bristol Myers Squibb: Consultancy, Other: Speaker fees; Adaptive: Consultancy; AbbVie: Consultancy; Vor Biopharma: Other: Speaker fees; Oncopeptides: Consultancy; Novartis: Consultancy; Sanofi: Consultancy; 10X Genomics: Consultancy; Regeneron: Consultancy, Other: Speaker fees; PreDICTA Bioscience: Consultancy, Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees, Other: Co-founder; Disc Medicine: Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees.
